[Skip to Content]
[Skip to Content Landing]
Other Articles
April 15, 1961

Tolbutamide in Treatment of Multiple Sclerosis and Parkinsonism

Author Affiliations

Division of Neurology The Medical School University of Minnesota Minneapolis 14, Minn.

JAMA. 1961;176(2):166. doi:10.1001/jama.1961.03040150082022

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  It is my belief that typical multiple sclerosis (the condition occurring in young individuals and characterized by remissions and exacerbations and scattered neurological findings) is not a specific disease but perhaps a syndrome resulting from a variety of alterations. The frequent finding of an elevated or diabetic glucose tolerance curve in the multiple sclerosis syndrome has been reported by several different authors. It is my present feeling, on the basis of preliminary studies, that the use of antidiabetic therapy will often have beneficial effects in those multiple sclerotic patients having an elevated or diabetic glucose tolerance curve. Those patients, even with the typical picture of multiple sclerosis but showing no change in the glucose tolerance test, do not show response to tolbutamide. Also, any symptoms which have been present for a long time are less likely to respond. The dosage of tolbutamide is 0.5 gm. (twice daily,

First Page Preview View Large
First page PDF preview
First page PDF preview